Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Safran

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
American Journal of Clinical Oncology|June 24, 2022
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318Rimini Breakstone, Khaldoun Almhanna, Alexander Raufi, et al.
American Journal of Clinical Oncology|December 7, 2020
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group TrialHeinrich Elinzano, Steven Toms, Jordan Robison, et al.
American Journal of Clinical Oncology|January 1, 2013
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II studyAriel Birnbaum, Thomas Dipetrillo, Ritesh Rathore, et al.
Journal of Translational Medicine|June 21, 2013
Cellular immunotherapy for refractory hematological malignanciesJohn L Reagan, Loren D Fast, Howard Safran, et al.
International Journal of Radiation Oncology, Biology, Physics|November 17, 2012
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canalLisa A Kachnic, Kathryn Winter, Robert J Myerson, et al.
American Journal of Clinical Oncology|August 3, 2005
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancerJames Y Tsai, David Iannitti, Anna Berkenblit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumorsAndrew X Zhu, Neal Ready, Jeffrey W Clark, et al.
Cancer Investigation|September 21, 2007
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II studyDevon Evans, Thomas Miner, David Iannitti, et al.
Cancer Medicine|August 29, 2014
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I studyEric S Winer, Howard Safran, Boguslawa Karaszewska, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704Timothy N Showalter, Kathryn A Winter, Adam C Berger, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
American Journal of Clinical Oncology|June 24, 2022
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318Rimini Breakstone, Khaldoun Almhanna, Alexander Raufi, et al.
American Journal of Clinical Oncology|December 7, 2020
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group TrialHeinrich Elinzano, Steven Toms, Jordan Robison, et al.
American Journal of Clinical Oncology|January 1, 2013
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II studyAriel Birnbaum, Thomas Dipetrillo, Ritesh Rathore, et al.
Journal of Translational Medicine|June 21, 2013
Cellular immunotherapy for refractory hematological malignanciesJohn L Reagan, Loren D Fast, Howard Safran, et al.
International Journal of Radiation Oncology, Biology, Physics|November 17, 2012
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canalLisa A Kachnic, Kathryn Winter, Robert J Myerson, et al.
American Journal of Clinical Oncology|August 3, 2005
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancerJames Y Tsai, David Iannitti, Anna Berkenblit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumorsAndrew X Zhu, Neal Ready, Jeffrey W Clark, et al.
Cancer Investigation|September 21, 2007
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II studyDevon Evans, Thomas Miner, David Iannitti, et al.
Cancer Medicine|August 29, 2014
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I studyEric S Winer, Howard Safran, Boguslawa Karaszewska, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704Timothy N Showalter, Kathryn A Winter, Adam C Berger, et al.
Pageof 12